Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Авторы: Nathan Paul, Hassel Jessica C., Rutkowski Piotr, Baurain Jean-Francois, Butler Marcus O., Schlaak Max, Sullivan Ryan J., Ochsenreither Sebastian, Dummer Reinhard, Kirkwood John M., Joshua Anthony M., Sacco Joseph J., Shoushtari Alexander N., Orloff Marlana, Piulats Josep M., Milhem Mohammed, Salama April K.S., Curti Brendan, Demidov Lev, Gastaud Lauris, Mauch Cornelia, Yushak Melinda, Carvajal Richard D., Hamid Omid, Abdullah Shaad E., Holland Chris, Goodall Howard, Piperno-Neumann Sophie
Журнал: New England Journal of Medicine
Том: 385
Номер: 13
Год издания: 2021
Издательство: Massachusetts Medical Society
Местоположение издательства: United States
Первая страница: 1196
Последняя страница: 1206
DOI: 10.1056/nejmoa2103485
Аннотация: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells.
Добавил в систему: Демидов Лев Вадимович

	ИСТИНА	Войти в систему Регистрация
	Интеллектуальная Система Тематического Исследования НАукометрических данных
	Главная Поиск Статистика О проекте Помощь

ИСТИНА